SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. announced publication of preclinical data suggesting that AV-101, its lead drug candidate for treatment of neurological disorders, may be useful for treating Parkinson’s disease. The data from studies conducted by VistaGen and collaborators in Dr. Sophie Erhardt’s laboratory at the Karolinska Institute in Sweden appeared in the peer-reviewed Journal of Neuropharmacology1. VistaGen is a platform-enabled biopharmaceutical company applying embryonic stem cell technologies to discover, develop and commercialize small molecule drugs and protein therapeutics for diabetes and neurological disorders.
